Kaleido Biosciences, Inc

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.

Biomodels in Waltham offers a wide range of preclinical research services, specializing in contract services for biopharmaceutical companies. Their experienced team provides comprehensive preclinical CRO services to support the development of innovative therapies and drug candidates. Generated from their website's infomation

Translate Bio is a biotechnology company based in Lexington, MA that focuses on developing mRNA therapeutics for various diseases. The company's research and development efforts are centered around leveraging mRNA technology to create potential treatments for a range of medical conditions. Translate Bio's work in the field of mRNA therapeutics aims to address unmet medical needs and advance the understanding of this innovative approach to healthcare. Through its research initiatives, the company seeks to contribute to the advancement of personalized medicine and improve patient outcomes. Generated from their business information